NICE’s recommendation of idebenone (Raxone) for Leber hereditary optic neuropathy offers hope for patients against visual impairment. Medscape News UK
Tag: News Alert
FDA Approves of VIZZ Eye Drops to Treat Presbyopia
The effects of once-daily acelidine-based treatment last for up to 10 hours. Medscape Medical News
FDA Approves VIZZ Eye Drops to Treat Presbyopia
The effects of once-daily acelidine-based treatment last for up to 10 hours. Medscape Medical News
MHRA Approves First UK Treatment for Thyroid Eye Disease
The Medicines and Healthcare products Regulatory Agency has approved teprotumumab, the first treatment to be licensed in the UK for adults with thyroid eye disease. Medscape News UK
FDA Okays Upadacitinib for Giant Cell Arteritis
This is the first and only oral JAK inhibitor indicated for giant cell arteritis, according to the manufacturer AbbVie. Medscape Medical News
FDA Approves First and Only Therapy for IgG4-RD
The CD19+ B-Cell targeted therapy reduced flare risk by 87% in a phase 3 clinical trial. Medscape Medical News
EMA Recommends Ryjunea for Pediatric Myopia
The atropine-based eye drop is designed to slow myopia progression in children. Medscape Medical News
Two New Drugs Approved for Age-Related Macular Degeneration
The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its refusal of marketing authorization for Syfovre. Medscape Medical News
New Drugs Turned Down by EU Safety Assessor
Drugs for ALS, age-related macular degeneration, and Duchenne muscular dystrophy did not get the green light due to lack of evidence. Medscape Medical News
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Unlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation. Medscape Medical News
FDA OKs High Concentration of Adalimumab Biosimilar Cyltezo
Unlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation. Medscape Medical News
CDC Investigating Reactions Linked to Counterfeit ‘Botox’
Reactions have included blurry vision, double vision, drooping eyelids, difficult swallowing or breathing, and other symptoms of botulism. MDedge News
FDA OKs Ninth Humira Biosimilar, With Interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available later this month. Medscape Medical News
FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness
"The approval of SYFOVRE is the most important event in retinal ophthalmology in more than a decade." FDA Approvals
FDA Approves Botox Challenger Daxxify for Frown Lines
DaxibotulinumtoxinA-lanm is the first and only peptide-formulated neuromodulator to reduce frown lines, with results lasting longer than conventional neuromodulators, according to the manufacturer. Medscape Medical News
White House Declares Monkeypox a Public Health Emergency
Intradermal injections that use one fifth of the normal dose of the Jynneos vaccine will extend the limited reach of the current supply, which is under high demand. Medscape Medical News
FDA Approves Brolucizumab for Diabetic Macular Edema
Brolucizumab wins approval for diabetic macular edema but with a warning of retinal vasculitis and retinal vascular occlusion. FDA Approvals
New Contact Lens Elutes Antihistamine for Ocular Allergy
A new contact lens that elutes antihistamine has been approved by the US Food and Drug Administration as a treatment for ocular allergies. FDA Approvals
FDA Approves Faricimab for nAMD and Diabetic Macular Edema
The US Food and Drug Administration has approved faricimab, a drug with the potential to reduce the number of injections needed to treat diabetic macular edema and neovascular age-related macular degeneration. FDA Approvals
Novel Drug, First Tx for Rare Uveal Melanoma
A novel drug, the first in its class, is also the first treatment approved for use in uveal melanoma, a rare cancer of the eye, after it was shown to improve overall survival. FDA Approvals